Insulin Diluting Medium For Novolog Injection, Solution
NDC Package 0169-2001-90
Package Information
Insulin Diluting Medium For Novolog (water injection) injection is nOVOLOG is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. This formulation utilizes a injection, solution delivery system. Marketed by Novo Nordisk, this product is identified by NDC 0169-2001 and is authorized under FDA application BLA020986.
Identification & Billing
- RxCUI: 1653196 - insulin aspart 100 UNT/ML in 3 ML Cartridge
- RxCUI: 1653196 - 3 ML insulin aspart, human 100 UNT/ML Cartridge
- RxCUI: 1653196 - insulin, aspart, human 100 UNT/ML per 3 ML Cartridge
- RxCUI: 1653198 - NovoLOG 100 UNT/ML in 3 ML Cartridge
- RxCUI: 1653198 - 3 ML insulin aspart, human 100 UNT/ML Cartridge [NovoLog]
Clinical Specifications
- Intravenous - Administration within or into a vein or veins.
- Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Regulatory & Marketing
Hierarchy Structure
- 0169 - Novo Nordisk
- 0169-2001 - Insulin Diluting Medium For Novolog
- 0169-2001-90 - 1 VIAL, GLASS in 1 CARTON / 10 mL in 1 VIAL, GLASS
- 0169-2001 - Insulin Diluting Medium For Novolog
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0169-2001-90 identifies a specific commercial package of 1 vial, glass in 1 carton / 10 ml in 1 vial, glass of Insulin Diluting Medium For Novolog, a human prescription drug labeled by Novo Nordisk. This injection, solution is formulated for intravenous; subcutaneous use and contains water as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novo Nordisk on August 27, 2001. The current certification is valid through December 31, 2026.
How is this Novo Nordisk product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00169200190. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.